Continual reassessment methods in phase I trials of the combination of two drugs in oncology

Statistics in Medicine

Volumn 18, Issue 14, 1999, Pages 1849-1864

  Kramar, Andrew ^a,d   Lebecq, Anne ^b   Candalh, Emmanuel ^c  

^a Regl Cancer Ctr Val d   (France)

^b SANOFI   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; IRINOTECAN;

BLOOD TOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; MAXIMUM PERMISSIBLE DOSE; NEUTROPENIA; ONCOLOGY; PHASE 1 CLINICAL TRIAL; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; CAMPTOTHECIN; CLINICAL TRIALS, PHASE I; COMPUTER SIMULATION; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIKELIHOOD FUNCTIONS; NEOPLASMS; NEUTROPENIA; PACLITAXEL; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 0033618612     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0258(19990730)18:14<1849::AID-SIM222>3.0.CO;2-I     Document Type: Conference Paper

References (25)

1. DeVita, V. T. 'Principles of cancer management: chemotherapy' in DeVita, V. T., Hellman, S. and Rosenberg, S. A. (eds), Cancer: Principles and Practice of Oncology, 5th edn, Lippincott-Raven Publishers, 1997.
2. Arbuck, S. G. 'Workshop on phase I study design', Annals of Oncology, 7, 567-573 (1996).
3. Mani, S. and Ratain, M. J. 'New phase I trial methodology', Seminars in Oncology, 24, 2, 253-261 (1997).
4. Von Hoff, D., Kuhn, J. and Clark, G.M. 'Design and conduct of phase I trials' in Buyse, M. E., Staquet, M. J. and Sylvester, R. J. (eds), Cancer Clinical Trials: Methods and Practice, Oxford University Press, 1985.
5. Dent, S. F. and Eisenhauer, E. A. 'Phase I trial design: Are new methodologies being put into practice?', Annals of Oncology, 7, 561-566 (1996).
6. O'Quigley, J., Pepe, M. and Fisher, L. 'Continual reassessment method: a practical design for phase I clinical trials in cancer', Biometrics, 46, 33-48 (1990).
7. Ratain, M. J., Mick, R., Schilsky, R. L. and Siegler, M. 'Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents', Journal of the National Cancer Institute, 85, 20, 1637-1643 (1993).
8. Faries, D. 'Practical modifications of the continual ressessment method for phase I cancer clinical trials', Journal of Biopharmaceutical Statistics, 4, 2, 147-164 (1994).
9. Storer, B. E. 'Design and analysis of phase I clinical trials', Biometrics, 45, 925-937 (1989).
10. Gordon, N. H. and Willson, J. K. V. 'Using toxicity grades in the design and analysis of cancer phase I clinical trials', Statistics in Medicine, 11, 2063-2075 (1992).
11. Evans, W. E. 'Alternative approaches for phase I studies of anticancer drugs: a role for therapeutic drug monitoring', Therapeutic Drug Monitoring, 15, 492-497 (1993).
12. Mick, R. and Ratain, M. J. 'Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision', Journal of the National Cancer Institute, 85, 3, 217-223 (1993).
13. Kerr, D. J. 'Phase I clinical trials: Adapting methodology to face new challenges', Annals of Oncology, 5, (Suppl.4), S67-S70 (1994).
14. Daughtery, C., Lyman, K., Minami, H., Cooper, N., Mick, R., Vogelzang, N., Stadler, W., Siegler, M. and Ratain, M. J. 'A feasibility study of informed consent and medical decision-making employing an interactive patient choice design in phase I trials', Proceedings of the Annual Meeting of the American Society of Clinical Oncolgists, 15, A352 (1996).
15. Durham, S. D., Flournoy, N. and Rosenberger, W. F. 'A random walk rule for phase I clinical trials', Biometrics, 53, 745-760 (1997).
16. Simon, R., Freidlin, B., Rubinstein, L., Arbuck, S. G., Collins, J. and Christian, M. C. 'Accelerated titration designs for phase I clinical trials in oncology', Journal of the National Cancer Institute, 89, 15, 1138-1147 (1997).
17. O'Quigley, J. and Shen, L. Z. 'Continual reassessment method: a likelihood approach', Biometrics, 52, 673-684 (1996).
18. Goodman, S. M., Zahurak, M. R. and Piantadosi, S. 'Some practical improvements in the continual reassessment method for phase I studies', Statistics in Medicine, 14, 1149-1161 (1995).
19. Berenbaum, M. C. 'The expected effect of a combination of agents: the general solution', Journal of Theoretical Biology, 114, 413-431 (1985).
20. Extra, J. M., Rousseau, F., Bruno, R., Clavel, M., Le Bail, N. and Marty, M. 'Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion', Cancer Research, 53, 1037-1042 (1993).
21. Abigerges, D., Chabot, G. G., Armand, J. P., Herait, P., Gouyette, A. and Gandia, D. 'Phase I and pharmacologic studies of the Camptothecin Analog Irinotecan administered every 3 weeks in cancer patients', Journal of Clinical Oncology, 13, 1, 210-221 (1995).
22. Couteau, C., Lokiec, F., Vernillet, L., Santoni, J., Baille, P., Borrits, D., Oulid-Aïssa, D., Soulas, F. and Armand, J. P. 'Phase I dose finding and pharmacokinetic (PK) study of docetaxel (D) in combination with Irinotecan (I) in advanced solid tumors', Proceedings of the Annual Meeting of the American Society of Clinical Oncolgists, 16, A709 (1997).
23. Korn, E. L. and Simon, R. 'Using tolerable-dose diagrams in the design of phase I combination chemotherapy trials', Journal of Clinical Oncology, 11, 4, 794-801 (1993).
24. Piantadosi, S. and Liu, G. 'Improved designs for dose escalation studies using pharmacokinetic measurements', Statistics in Medicine, 15, 1605-1618 (1996).
25. Moller, S. 'An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses', Statistics in Medicine, 14, 911-922 (1995).